Loading...
Much has been written about the effects on quality of life of moderate to severe menopausal vasomotor symptoms (VMS), which can persist for many years (NEJM JW Womens Health Mar 10 2015; [e-pub] and JAMA Intern Med 2015 Feb 16; [e-pub]). In a retrospective cohort study, researchers addressed the financial cost of VMS. Using a health insurance claims database for 60 self-insured Fortune 500 companies in the U.S., investigators matched 252,273 women with untreated VMS in a 1:1 ratio to women without VMS (by age, region, payer type, employer industry, hysterectomy history, and menopause-related diagnoses). Work loss data were available for about half the companies.
In a 12-month period, the VMS cohort had significantly more all-cause and VMS-re…